Basal cell carcinoma - Basalzellkarzinom
☆ AI Dermatology — Free Service
An den 2022 Stiftung Warentest Resultater aus Däitschland war d'Zefriddenheet vum Konsument mam ModelDerm nëmme liicht manner wéi mat bezuelte Telemedizin Konsultatiounen.
An den 2022 Stiftung Warentest Resultater aus Däitschland war d'Zefriddenheet vum Konsument mam ModelDerm nëmme liicht manner wéi mat bezuelte Telemedizin Konsultatiounen.
Ulceréiert Läsionen, déi d'Haut vun der Nues bei engem eeleren Individuum beaflossen, ginn dacks als Basalzellkarzinom (Basal cell carcinoma) diagnostizéiert. D'Nues ass e gemeinsame Site vum Optriede fir dës Zort Hautkriibs.
Basalzellkarzinom (Basal cell carcinoma) kann mat onregelméissegen Grenzen an Ulcere presentéieren.
Basalzellkarzinom (Basal cell carcinoma) kann fir Warze verwiesselt ginn.
relevance score : -100.0%
ReferencesBasal cell carcinoma (BCC) ass déi heefegst Aart vu Hautkriibs. Sonneliicht Belaaschtung ass d'Haaptursaach. Bal all BCC Fäll weisen iwweraktiv Hedgehog Signaliséierung an der molekulare Analyse. Verschidde Behandlunge si verfügbar a gewielt baséiert op Widderhuelungsrisiko, Wichtegkeet vun der Tissuekonservatioun, Patient Präferenz, an Ausmooss vun der Krankheet.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basalzellkarzinom (Basal cell carcinoma) sinn déi heefegst Aart vu Hautkriibs bei Erwuessener mat helle Haut vu 50 a méi al. Hir Zuel geet weltwäit erop, haaptsächlech wéinst der Belaaschtung fir Sonneliicht. Bestëmmte genetesch Bedéngungen kënnen d'Leit ufalleg maachen fir dës Kriibs bei engem méi jonken Alter z'entwéckelen. Basalzellkarzinom (Basal cell carcinoma) variéieren an der Gravitéit, rangéiert vu liicht behandelbaren iwwerflächlechen oder noduläre Läsionen bis méi extensiv, déi Diskussioun a spezialiséierte medizinesche Teams erfuerderen. D'Prognose hänkt vun der Wahrscheinlechkeet vum Kriibs zréck oder seng Fäegkeet fir nawell Gewebe ze beschiedegen. Chirurgie ass d'Standardbehandlung fir déi meescht Fäll, suergt fir präzis Entfernung a geréng Chancen op Widderhuelung. Manner invasiv Methoden kënnen effektiv iwwerflächlech Läsionen behandeln.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Déi primär Behandlung fir BCC ass Chirurgie. Fir héich-Risiko oder widderhuelend BCC, besonnesch a kritesche Beräicher, gëtt mikrografesch kontrolléiert Chirurgie recommandéiert. Patienten mat niddereg-Risiko iwwerflächlech BCC kënnen topisch Behandlungen oder destruktiv Methoden berücksichtegen. Photodynamisch Therapie funktionnéiert gutt fir iwwerflächlech a niddereg-Risiko nodular BCCs. Fir lokal fortgeschratt oder metastatesch BCC, Hedgehog Inhibitoren (vismodegib, sonidegib) si recommandéiert. Wann d'Krankheet Fortschrëtter oder Intoleranz zu Hedgehog Inhibitoren ass, kann Immuntherapie mat anti-PD1 antibody (cemiplimab) berücksichtegt ginn. Radiotherapie ass eng gutt Optioun fir Patienten déi keng Chirurgie kënnen hunn, besonnesch eeler Patienten. Elektrochemotherapie kéint berücksichtegt ginn wann Chirurgie oder Radiotherapie keng Optioun ass.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Risikofaktoren enthalen Expositioun fir ultraviolett Liicht, Stralungstherapie, laangfristeg Expositioun fir Arsen a schlecht Immunsystemfunktioun (z.B. Organtransplantatioun). UV-Beliichtung während der Kandheet ass besonnesch schiedlech.
No der Diagnostik duerch Biopsie ass d'Behandlung typesch duerch chirurgesch Entfernung. Dëst kann duerch einfach Exzision (excision) ginn wann de Kriib (cancer) kleng ass; wann de Kriib net kleng ass, ass Mohs-Chirurgie allgemeng recommandéiert.
Basalzellkarzinom macht mindestens 32 % vun allen Kriib (cancer) weltwäit aus. Vun anere Hautkriibë wéi Melanom sinn ongeféier 80 % Basalzellkarzinom. An den USA sinn ongeféier 35 % vu wäiss Männer a 25 % vu wäiss Fraen irgendwann an hirem Liewen duerch Basalzellkarzinom betraff.
○ Diagnos a Behandlung
#Dermoscopy
#Skin biopsy
#Mohs surgery